Cargando…

TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer

PURPOSE: Trophoblast cell surface antigen 2 (TROP2) has emerged as a promising target of antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC), as well as other breast cancers (BCs). This study aims to investigate the biomarker value of TROP2 for patient-tailoring and prognostic f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaoyue, Zhou, Tianhao, Wang, Yongmei, Pei, Min, Wang, Guifeng, Chu, Wendi, Wang, Qi, Du, Shaoqian, Wang, Hongxia, Wang, Chunhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078428/ https://www.ncbi.nlm.nih.gov/pubmed/35535168 http://dx.doi.org/10.2147/OTT.S354048

Ejemplares similares

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
por: Mu, Songlin, et al.
Publicado: (2022)

Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer
por: Kushiyama, Shuhei, et al.
Publicado: (2021)

Trop-2 Is a Determinant of Breast Cancer Survival
por: Ambrogi, Federico, et al.
Publicado: (2014)

Trop-2 as a Therapeutic Target in Breast Cancer
por: Sakach, Elizabeth, et al.
Publicado: (2022)

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker
por: Chen, Yuning, et al.
Publicado: (2021)

Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
por: Vranic, Semir, et al.
Publicado: (2022)

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer
por: Cardillo, Thomas M., et al.
Publicado: (2020)

ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants
por: Ou, Jianxia, et al.
Publicado: (2022)

Trop2 is overexpressed in gastric cancer and predicts poor prognosis
por: Zhao, Wei, et al.
Publicado: (2015)

Trop petits pour Dieu /
por: Laederach, Monique, 1938-
Publicado: (1986)

Une trop bruyante solitude/
por: Hrabal, Bohumil, 1914-1997
Publicado: (1983)

Une fin trop précoce?
por: Rayson, Daniel
Publicado: (2022)

Correction: Trop-2 Is a Determinant of Breast Cancer Survival
Publicado: (2014)

TROP2 methylation and expression in tamoxifen-resistant breast cancer
por: Zimmers, Stephanie M., et al.
Publicado: (2018)

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
por: Chu, Wendi, et al.
Publicado: (2022)

Identification and Characterization of Specific Nanobodies against Trop-2 for Tumor Targeting
por: Hu, Yaozhong, et al.
Publicado: (2022)

Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis
por: Zeng, Ping, et al.
Publicado: (2016)

TROP2 modulates the progression in papillary thyroid carcinoma
por: Sun, Huali, et al.
Publicado: (2021)

The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer
por: Mao, Yuan, et al.
Publicado: (2016)

Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer
por: Liu, Donglin, et al.
Publicado: (2014)

Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements
por: Yao, Liqin, et al.
Publicado: (2023)

Trop-2 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

Analgesic effects of nerve growth factor‐directed monoclonal antibody on diabetic neuralgia in an animal model
por: Dong, Xingchen, et al.
Publicado: (2022)

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
por: Raji, Rhoda, et al.
Publicado: (2011)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
por: Sperger, Jamie M., et al.
Publicado: (2023)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022)

ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma
por: Yang, Wendi, et al.
Publicado: (2023)

The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms
por: Liu, Haiyan, et al.
Publicado: (2017)

Targeting Trop-2 in solid tumors: future prospects
por: Zaman, Saif, et al.
Publicado: (2019)

Contrôles anti-dopage : trop, pas assez, autrement ?
por: Kintz, Pascal
Publicado: (2020)

Trop2: Jack of All Trades, Master of None
por: Lenárt, Sára, et al.
Publicado: (2020)

TROP2 Expression in Sebaceous and Sweat Gland Carcinoma
por: Ito, Takamichi, et al.
Publicado: (2022)

Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment
por: Sun, Xia, et al.
Publicado: (2021)

Amelioration of Congenital Tufting Enteropathy in EpCAM (TROP1)-Deficient Mice via Heterotopic Expression of TROP2 in Intestinal Epithelial Cells
por: Nakato, Gaku, et al.
Publicado: (2020)

Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
por: Jeon, Yeonjin, et al.
Publicado: (2022)

Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer
por: Izci, Hava, et al.
Publicado: (2022)

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
por: Jeong, Jae Ho, et al.
Publicado: (2022)

Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints
por: Huang, Yida, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_65vmo4qd51f32ojnq2k83b40b9